InvestorsHub Logo
Followers 11
Posts 586
Boards Moderated 0
Alias Born 08/31/2020

Re: dloggold post# 18544

Thursday, 09/24/2020 10:16:21 PM

Thursday, September 24, 2020 10:16:21 PM

Post# of 43363
I’m pretty confident it will save lives. But more interested in preventing lung damage and hypoxia brain damage. There will be long term damage from the cytokine storm in both those areas. I would say x 20 of death rate we have seen worldwide Based on patients I see at hospital. There is this COVID Confusion majority have which is unique (some I don’t think is hypoxia related from sats I take with ambulation) . But Most patients don’t go to hospital and especially won’t get admitted to hospital until O2 sats <92%. Most likely indicating cytokine storm is starting to be triggered, so these mild to moderate studies will only help some. Patient usually get to moderate severe stage within couple of days in hospital. Right now it’s just remesdivir and dexamethsone for treatment in tampa with some RA drugs. Personally from reading I’m concerned with side effects of dexamethsone and possibility of neurotoxicity (which lenz most likely doesn’t From their research). The big question I had for lenzilumab Is the timing of dosing for best outcome. Last presentation at the opph whatever I feel was the first time it was mentioned when they try to give it which was good for me.

But there are a lot of drugs coming. I’m a PT I don’t know cancer DMARDs much. But with Gilead RA drug fail maybe they want lenz also to try a RA study down road with obv a side by side for lung diseases with steroids vs lenz. They are taking their time with study for reasons. COVID is one peace to their puzzle. If study is good they will get endless funding for studies for RA Car T COPD asthma MS etc
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.